Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx quinine sulfate for treating leg cramps requires NDA/ANDA approval, FDA informs 44 firms.

Executive Summary

Rx QUININE SULFATE FOR LEG CRAMPS IS "NEW DRUG" REQUIRING APPROVAL of an NDA or ANDA to remain on the market, FDA said in a Jan. 23 warning letter sent to 44 companies. The agency action follows a Sept. 8 citizen petition from Public Citizen's Health Research Group requesting that FDA extend to prescription products its decision that OTC quinine products are not generally recognized as safe and effective for leg cramps ("The Pink Sheet" Sept. 12, 1994, T&G-4).

You may also be interested in...

Mutual Quinine Approved For Malaria; Unapproved Versions Could Be Pulled

FDA will hold an internal meeting in early September to discuss the fate of unapproved quinine products on the market following its first NDA approval for quinine sulfate to treat malaria

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts